Enoxaparin

serpin family C member 1 ; Homo sapiens







26 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34790076 Antithrombin III Supplementation in a Premature Infant: Is There a Target Antithrombin Level? 2021 1
2 31986476 Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients. 2020 Mar 1
3 30262570 THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. 2019 Apr 1
4 30181723 Effect of Exogenous Antithrombin Administration on Anti-Xa Levels in Infants Treated With Enoxaparin. 2018 Jul-Aug 5
5 28282887 New Insights in Thrombin Inhibition Structure-Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin. 2017 Mar 8 1
6 29031112 Quantitative analysis of antithrombin III binding site in low molecular weight heparins by exhausetive heparinases digestion and capillary electrophoresis. 2017 Nov 15 1
7 26758598 Screening enoxaparin tetrasaccharide SEC fractions for 3-O-sulfo-N-sulfoglucosamine residues using [(1)H,(15)N] HSQC NMR. 2016 Feb 1
8 26280926 Analytical and statistical comparability of generic enoxaparins from the US market with the originator product. 2015 Nov 10 1
9 24375987 Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. 2014 Jun 2
10 24616065 Affinity capillary electrophoresis for the determination of binding affinities for low molecular weight heparins and antithrombin-III. 2014 May 1
11 17489664 Enoxaparin in acute coronary syndromes. 2007 May 1
12 17600038 Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. 2007 Sep 1
13 17621651 Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. 2007 Nov 15 4
14 16675258 Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. 2006 Jun 1
15 16685318 Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 2006 May 1 1
16 15860994 Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction. 2005 Spring 1
17 15957976 Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes. 2005 Jun 1
18 16124953 A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. 2005 Apr 1
19 15210403 Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. 2004 Apr 30 1
20 15238596 Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 2004 Jul 7 1
21 11812067 Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. 2002 Feb 1
22 11287128 Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. 2001 Apr 3 1
23 11755953 The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer. 2001 Dec 15 1
24 14728009 Enoxaparin: in the prevention of venous thromboembolism in medical patients. 2001 2
25 8165617 Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. 1993 Dec 20 1
26 1848441 Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. 1991 Feb 2